XIAP and chronic myelogenous leukemia, BCR-ABL1 positive: Knockdown of XIAP effectively inhibits the proliferation of K562 cells, increases the apoptosis rate, and effectively reverses CML resistance (Lima et al., 2006; Seca et al., 2011).